Comparative effectiveness and safety of bolus vs. continuous infusion of loop diuretics: Results from the MIMIC-III Database

被引:1
|
作者
Weng, Haoyu [1 ]
Li, Yuxi [1 ]
Nie, Xiaolu [2 ]
He, Chunhui [3 ]
Feng, Pengbin [4 ]
Zhao, Fengxin [4 ]
Chen, Qingjie [5 ]
Sun, Wen [6 ]
Jiang, Jie [1 ]
Zhang, Yan [1 ]
Huo, Yong [1 ]
Li, Jianping [1 ]
机构
[1] Peking Univ First Hosp, Dept Cardiol, Beijing, Peoples R China
[2] Beijing Childrens Hosp, Ctr Clin Epidemiol & Evidence Based Med, Beijing, Peoples R China
[3] Chinese Acad Med Sci, Dept Cardiol, Fuwai Hosp, Beijing, Peoples R China
[4] Beijing 1M data Tech Co Ltd, Beijing, Peoples R China
[5] Xinjiang Med Univ, Dept Cardiol, Affiliated Hosp 1, Urumqi, Xinjiang, Peoples R China
[6] Peking Univ First Hosp, Dept Respirat & Crit Care, Beijing, Peoples R China
来源
关键词
Loop diuretics; Continuous infusion; Bolus injection; Urine output; Acute kidney injury incidence; MIMIC-III data-base; DECOMPENSATED HEART-FAILURE; CRITICALLY-ILL PATIENTS; INTENSIVE-CARE-UNIT; STRATEGIES; PATIENT; KIDNEY; SAPS-3;
D O I
10.1016/j.amjms.2022.12.013
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: It is unclear whether fluid management goals are best achieved by bolus injection or continuous infusion of loop diuretics. In this study, we compared the effectiveness and safety of a continuous infusion with that of a bolus injection when an increased loop diuretic dosage is required in intensive care unit (ICU) patients.Methods: We obtained data from the MIMIC-III database for patients who were first-time ICU admissions and required an increased diuretic dosage. Patients were excluded if they had an estimated glomerular filtration rate <15 ml/min/1.73 m2, were receiving renal replacement therapy, had a baseline systolic blood pressure <80 mmHg, or required a furosemide dose <120 mg. The patients were divided into a continuous group and a bolus group. Propensity score matching was used to bal-ance patients' background characteristics.Results: The final dataset included 807 patients (continuous group, n = 409; bolus group, n = 398). After propensity score matching, there were 253 patients in the bolus group and 231 in the continuous group. The 24 h urine output per 40 mg of furosemide was significantly greater in the continuous group than in the bolus group (234.66 ml [95% confidence interval (CI) 152.13-317.18, p < 0.01]). There was no significant between-group difference in the incidence of acute kidney injury (odds ratio 0.96, 95% CI 0.66-1.41, p = 0.85).Conclusions: Our results indicate that a continuous infusion of loop diuretics may be more effective than a bolus injection and does not increase the risk of acute kidney injury in patients who need an increased diuretic dosage in the ICU.
引用
收藏
页码:353 / 360
页数:8
相关论文
共 37 条
  • [31] PARTICIPANT RETENTION AND ADHERENCE IN BEHAVIORAL TRIALS: EARLY RESULTS FROM AN ONGOING PREFERENCE-BASED COMPARATIVE EFFECTIVENESS TRIAL OF MINDFULNESS BASED CANCER RECOVERY VS. TAICHI/QIGONG FOR CANCER SURVIVORS (THE MATCH STUDY)
    Oberoi, Devesh V.
    Piedlue, Katherine-Ann
    Guirgis, Steven
    Pirbhai, Hassan
    Mina, Daniel Santa
    Jones, Jennifer M.
    Carlson, Linda E.
    PSYCHOSOMATIC MEDICINE, 2019, 81 (04): : A138 - A138
  • [32] Preliminary toxicity results of a randomized phase III trial of the TTD Group comparing Capecitabine and Oxaliplatin (CapeOx) vs. Oxaliplatin and 5-Fluorouracil in continuous infusion (5-FU CI) as first line treatment in advanced or metastatic colorectal cancer (CRC)
    Aranda, Enrique
    Sastre, Javier
    Gomez-Espana, Auxiliadora
    Chaves, Manuel
    Carrato, Alfredo
    Aparicio, Jorge
    Maestu, Inmaculada
    Tabernero, Jose M.
    Reina, Juan J.
    Diaz-Rubio, Eduardo
    ANNALS OF ONCOLOGY, 2004, 15 : 82 - 82
  • [33] The Comparative Effectiveness and Safety of Cangrelor vs. In-lab Glycoprotein IIb/IIIa Inhibitor (GPI) in Patients Undergoing Percutaneous Coronary Intervention: Insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2)
    Siddiqui, Saifullah
    Seth, Milan
    Sukul, Devraj
    Madder, Ryan
    Rizk, Maged
    Walchak, Eric
    Ruwende, Cyril
    Saltiel, Frank
    Zainea, Mark
    Changezi, Hameem
    Gurm, Hitinder
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 72 (13) : B256 - B257
  • [34] Long-Term Efficacy and Safety of Recombinant Interferon Alpha-2 Vs. Hydroxyurea in Polycythemia Vera: Preliminary Results from the Three-Year Analysis of the Daliah Trial - a Randomized Controlled Phase III Clinical Trial
    Knudsen, Trine Alma
    Hansen, Dennis Lund
    Ocias, Lukas Frans
    Bjerrum, Ole Weis
    Brabrand, Mette
    El Fassi, Daniel
    Frederiksen, Mikael
    Kjaer, Lasse
    Kristensen, Thomas Kielsgaard
    Kruse, Torben A.
    Mourits-Andersen, Torben
    Moller, Peter
    Overgaard, Ulrik Malthe
    Severinsen, Marianne Tang
    Skov, Vibe
    Stentoft, Jesper
    Starklint, Jorn
    de Stricker, Karin
    Thomassen, Mads
    Larsen, Thomas Stauffer
    Hasselbalch, Hans Carl
    BLOOD, 2018, 132
  • [35] Efficacy and Safety Results From ASCEMBL, a Phase III Study of Asciminib vs. Bosutinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After.2 Prior Tyrosine Kinase Inhibitors (TKIs): Week 96 Update
    Rea, Delphine
    Hochhaus, Andreas
    Mauro, Michael J.
    Minami, Yosuke
    Lomaia, Elza
    Voloshin, Sergey
    Turkina, Anna
    Kim, Wook
    Apperley, Jane F.
    Cortes, Jorge E.
    Abdo, Andre
    Fogliatto, Laura Marie
    Kim, Dennis Dong Hwan
    le Coutre, Philipp
    Saussele, Susanne
    Annunziata, Mario
    Hughes, Timothy P.
    Chaudhri, Naeem
    Chee, Lynette
    Garcia-Gutierrez, Valentin
    Sasaki, Koji
    Kapoor, Shruti
    Allepuz, Alex
    Quenet, Sara
    Bedoucha, Veronique
    Boquimpani, Carla
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S295 - S296
  • [36] First efficacy and safety results from XELOX-1/NO16966, a randomised 2x2 factorial phase III trial of XELOX vs. FOLFOX4+bevacizumab or placebo in first-line metastatic colorectal cancer (MCRC)
    Cassidy, Jim
    Clarke, Stephen
    Rubio, Eduardo Diaz
    Scheithauer, Werner
    Figer, Arie
    Wong, Ralph
    Koski, Sheryl
    Lichinitser, Mikhail
    Yang, Tsai-Shen
    Saltz, Leonard
    ANNALS OF ONCOLOGY, 2006, 17
  • [37] Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK-Inhibitor-Naive ALK plus Non-Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Study
    Ahn, Myung J.
    Kim, Hye R.
    Yang, James C. H.
    Han, Ji-Yu
    Li, Jacky Yu-Chung
    Hochmair, Maximilian J.
    Chang, Gee-Chen
    Delmonte, Angelo
    Lee, Ki H.
    Campelo, Rosario G.
    Gridelli, Cesare
    Spira, Alexander, I
    Califano, Raffaele
    Griesinger, Frank
    Ghosh, Sharmistha
    Felip, Enriqueta
    Kim, Dong-Wan
    Liu, Yuyin
    Zhang, Pingkuan
    Popat, Sanjay
    Camidge, D. Ross
    CLINICAL LUNG CANCER, 2022, 23 (08) : 720 - 730